Ribociclib in early breast cancer: interpreting the 4-year outcomes of the NATALEE trial

Clinical background and unmet need

Hormone receptor-positive (HR+), ERBB2-negative early breast cancer (EBC) remains characterized by a prolonged risk of recurrence that extends well beyond the initial years following diagnosis (1). Despite the established benefit of adjuvant endocrine therapy (ET), distant recurrences continue to occur decades later, underscoring a persistent unmet need for durable risk reduction strategies (2). In this context, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have emerged as a transformative class in advanced disease management, prompting intense investigation into their role in the adjuvant setting.

Overview of the NATALEE trial

The exploratory 4-year analysis of the NATALEE trial reported by Fasching and colleagues provides critical insights into the durability of the benefit associated with adjuvant ribociclib plus ET after completion of the planned 3-year treatment period (3). Importantly, this analysis evaluates outcomes at a time when all patients had discontinued ribociclib, allowing assessment of whether clinical benefit persists beyond active CDK4/6 inhibition. The multicenter, randomized study design strengthens both external and internal validity. The open-label design was necessary as ribociclib requires frequent safety monitoring and dose adjustments. Ribociclib was administered at a reduced dose of 400 mg for 36 months. However, the extent to which this dose represents the optimal balance between efficacy and tolerability in the adjuvant setting remains uncertain. Variability in treatment exposure due to dose modifications and discontinuations may impact the observed efficacy and should be considered when interpreting trial outcomes. Invasive disease-free survival (iDFS) was the primary endpoint, with distant disease-free survival (DDFS) and overall survival (OS) as key secondary endpoints. At a median follow-up of 44.2 months, ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) continued to demonstrate a statistically significant and clinically meaningful improvement in iDFS compared with NSAI alone (hazard ratio 0.72). Notably, the absolute iDFS difference increased from 2.7% at 3 years to 4.9% at 4 years, with Kaplan-Meier curves continuing to separate after treatment cessation. This temporal pattern strongly suggests that ribociclib confers a lasting disease-modifying effect rather than a purely on-treatment suppression of recurrence. Ribociclib demonstrated a statistically significant improvement in DDFS, with a hazard ratio of approximately 0.73 and an absolute benefit of ~2–3% at 3 years. Inclusion of the DDFS as a secondary efficacy endpoint is appropriate, given its strong clinical relevance and direct association with mortality. However, the magnitude of absolute benefit remains modest, particularly in lower-risk populations. OS data are currently immature, with fewer than ~2% of patients experiencing death events at the time of analysis, limiting conclusions regarding long-term survival benefit. Whether improvements in iDFS and DDFS will ultimately translate into meaningful survival gains remains to be determined with extended follow-up.

Such findings are particularly relevant in HR+ EBC, where late recurrences predominate and distant metastases are largely incurable. The observation that most iDFS events in NATALEE were distant recurrences and that these were consistently reduced with ribociclib (hazard ratio for distant disease–free survival, ~0.73, with an absolute improvement of ~2–3% at 3 years)—highlights the clinical importance of sustained protection against micrometastatic disease. However, readers should interpret the iDFS with caution until OS data is mature. Given the relatively short follow-up (~44 months) in a disease characterized by late recurrences, and longer-term data are needed to confirm durability of benefit.

One of the defining features of NATALEE is its broad eligibility criteria, encompassing patients with stage II and III disease, including those with high-risk node-negative (N0) tumors. The 4-year analysis confirms that the iDFS and DDFS benefits of ribociclib were consistent across nodal status, anatomic stage, menopausal status, and Ki-67 subgroups. The benefit observed in patients with high-risk N0 disease is particularly noteworthy. Although the sample size of 5,100 patients was robust, the broad eligibility criteria (i.e., stage II–III), while enhancing generalizability, might have diluted treatment effects by including lower-risk populations, potentially underestimating benefit in patients at highest risk of recurrence. Additionally, despite the overall sample size being substantial, subgroup sample sizes—particularly for premenopausal populations—are considerably smaller, and corresponding event counts are limited. Thus, subgroup analyses should be interpreted cautiously. Historically, treatment escalation in the adjuvant setting has been largely restricted to node-positive populations. However, contemporary data demonstrate that biologically high-risk node-negative tumors carry recurrence risks comparable to those with limited nodal involvement. The NATALEE results reinforce the concept that risk stratification should extend beyond nodal status alone, supporting a more nuanced, biology-driven approach to adjuvant therapy intensification.

Safety and tolerability considerations

From a tolerability standpoint, the 4-year analysis revealed no new safety signals, with adverse event rates remaining stable compared with prior reports. The most common grade ≥3 adverse event associated with ribociclib was neutropenia, occurring in approximately 40–45% of patients, while hepatobiliary toxicity (elevated liver enzymes) and QT interval prolongation were less frequent but clinically relevant. Dose interruptions occurred in approximately 60–65% of patients, and dose reductions were required in ~45%, reflecting the need for ongoing toxicity management. Although approximately 20% of patients discontinued ribociclib early due to adverse events, most toxicities occurred early during treatment, and dose reductions did not appear to compromise efficacy. This reinforces the importance of proactive toxicity monitoring and management to maximize adherence and long-term benefit. The use of a lower starting dose (400 mg) and an intermittent dosing schedule may have contributed to the favorable balance between efficacy and tolerability observed in NATALEE. In routine clinical practice, such considerations are critical when recommending multi-year adjuvant therapy to patients who are otherwise disease-free and potentially cured.

Comparison with other adjuvant CDK4/6 trials

NATALEE must be interpreted alongside other adjuvant CDK4/6 inhibitor trials, most notably monarchE, which evaluated 2 years of abemaciclib in a more narrowly defined, high-risk node-positive population (3,4). Differences in patient selection, dosing schedule, and duration of therapy complicate direct cross-trial comparisons. Nevertheless, the sustained benefit seen in NATALEE beyond the 3-year treatment window raises important mechanistic considerations.

The longer duration of CDK4/6 inhibition in NATALEE was designed to promote prolonged cell-cycle arrest and potentially induce irreversible senescence in dormant tumor cells. Given that approximately half of recurrences in HR+ EBC occur beyond 5 years, extended suppression of cell-cycle re-entry may be particularly relevant. The continued separation of survival curves after ribociclib discontinuation lends empirical support to this biological rationale.

Clinical implications

The 4-year NATALEE data strengthen the evidence base supporting adjuvant ribociclib as a standard-of-care option for a broad population of patients with HR+/ERBB2-negative EBC at risk of recurrence. The durability of benefit beyond treatment completion distinguishes ribociclib within the adjuvant CDK4/6 inhibitor landscape and aligns with the long natural history of HR+ breast cancer. Despite its broad eligibility criteria, NATALEE predominantly enrolled a higher-risk, clinically selected population, which may limit the generalizability of its findings to lower-risk patients seen in routine practice. In addition, the open-label design and prolonged treatment duration raise considerations regarding long-term tolerability, adherence, and real-world feasibility.

Health system and implementation considerations

The integration of CDK4/6 inhibitors into the adjuvant management of hormone receptor–positive, ERBB2-negative EBC requires careful planning, especially in the U.S. healthcare setting. Treatment and practice guidelines, such as National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines and American Society of Clinical Oncology (ASCO), include guidance regarding the use of CDK4/6 inhibitors but need to be continuously updated as the OS data from these trials mature. Oncology institutions need to efficiently adapt to these evolving guidelines regarding CDK4/6 inhibitor use and plan for additional infrastructure and monitoring capacity, such as ongoing laboratory testing, periodic electrocardiographic surveillance, and active management of hematologic and hepatic toxicities.

Since CDK4/6 inhibitors are high-cost therapies, the economic burden and budget impact of expanding their use from metastatic to early-stage disease represent a pertinent concern (5). In the light of constrained resources, equitable access to CDK4/6 inhibitors represents a crucial challenge for patients, payers, and policymakers. Payers such as commercial insurers, Medicare Advantage plans, and pharmacy benefit managers (PBMs) frequently issue prior-authorization criteria that may be narrower than NCCN language. Step-therapy rules and documentation requirements may further delay real-world uptake (6). Thus, there is a need for rigorous health-economic modeling, long-term survival projections, and real-world utilization data to support the adoption of targeted adjuvant therapies in the treatment of EBC. Additionally, financial navigation infrastructure needs to be in place to support equitable uptake.

Implications for future research

Ongoing follow-up at 5 and 6 years, including OS analyses, will be essential to fully define the long-term impact of adjuvant CDK4/6 inhibition. Additionally, future work should focus on refining patient selection using clinical and molecular markers, optimizing treatment duration, and integrating patient-reported outcomes to better capture the lived experience of extended adjuvant therapy and its impact on quality of life.

Moving forward, as we continue to prepare for the integration of CDK4/6 inhibitors in EBC therapy, some pivotal questions need to be addressed. In the adjuvant setting, pivotal CDK4/6 inhibitor trials have demonstrated clinically meaningful reductions in recurrence risk, albeit in different patient populations and with distinct treatment strategies The NATALEE trial evaluated ribociclib administered at a lower dose (400 mg daily) for an extended duration of 3 years in a broad stage II–III population, including patients with node-negative but high-risk disease, and showed a significant improvement in iDFS compared with ET alone, with consistent benefit across nodal subgroups and increasing absolute benefit over time. In contrast, the monarchE trial investigated 2 years of adjuvant abemaciclib in a more selected, node-positive, high-risk population and demonstrated sustained improvements in iDFS and distant relapse-free survival, with an OS benefit emerging at longer follow-up (4). Collectively, these trials highlight both shared and distinct clinical roles of adjuvant CDK4/6 inhibition and underscore the importance of tailoring treatment selection based on patient risk profile and trial eligibility criteria. Firstly, the selection of patients who would benefit the most needs to be optimized, and one of the approaches to do so would be the identification of reliable biomarkers. Currently, clinical features such as tumor size, nodal involvement, grade, and proliferation indices inform treatment selection (7). However, the utilization of promising emerging tools such as genomic assays and circulating tumor DNA detection remains underutilized (7-9). Secondly, the ideal duration of therapy needs to be examined further. Prolonged treatment may suppress dormant metastatic disease and reduce late recurrence, but it is also associated with increased risk of cumulative toxicity, financial burden, and adherence challenges (10,11). Finally, as therapeutic options expand, the integration of CDK4/6 inhibition may become increasingly complex (12). Therefore, robust guidance regarding sequencing or combining these modalities needs to be in place to avoid therapeutic redundancy and excessive toxicity.

Conclusions

The exploratory 4-year analysis of NATALEE demonstrates that the benefit of adjuvant ribociclib extends beyond the active treatment period, with increasing absolute reductions in recurrence risk over time. These findings mark an important step forward in the quest to prevent late and distant recurrences in HR-positive EBC and support a paradigm shift toward sustained, biology-informed adjuvant intensification strategies. Continued follow-up, real-world evidence, and shared decision-making will be essential to ensure that clinical gains translate into meaningful, equitable, and patient-centered outcomes.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, AME Clinical Trials Review. The article has undergone external peer review.

Peer Review File: Available at https://actr.amegroups.com/article/view/10.21037/actr-26-0018/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://actr.amegroups.com/article/view/10.21037/actr-26-0018/coif). P.P.M. is an employee of UCB and holds stock or stock options in the company. S.G. is an employee of Neurocrine Biosciences, Inc. and holds stocks or stock options in the company. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Salvo EM, Ramirez AO, Cueto J, et al. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis. Breast 2021;57:5-17. [Crossref] [PubMed]
2. O’Shaughnessy J, Tolaney SM, Yardley DA, et al. Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer. Breast 2025;81:104437.
3. Fasching PA, Stroyakovskiy D, Yardley DA, et al. Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial. JAMA Oncol 2025;11:1364-72. [Crossref] [PubMed]
4. Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24:77-90. [Crossref] [PubMed]
5. Masurkar P, Borate S, Goswami S. Systematic review of postoperative opioid use after lobectomy for primary lung cancer patients PROSPERO 2023 [Internet]. [cited 2024 Jan 31]. Available online: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023454849
6. ecancer. ESMO 2019: New studies question whether novel anti-cancer drugs are worth their extra cost - ecancer [Internet]. [cited 2026 Feb 1]. Available online: http://ecancer.org/en/news/16676-esmo-2019-new-studies-question-whether-novel-anti-cancer-drugs-are-worth-their-extra-cost
7. Foldi J, O’Meara T, Marczyk M, et al. Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. J Clin Oncol 2019;37:1365-9. [Crossref] [PubMed]
8. Turner NC, Kingston B, Kilburn LS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol 2020;21:1296-308. [Crossref] [PubMed]
9. Tegeler CM, Hartkopf AD, Banys-Paluchowski M, et al. Circulating Tumor DNA in Early and Metastatic Breast Cance-Current Role and What Is Coming Next. Cancers (Basel) 2024;16:3919. [Crossref] [PubMed]
10. Niraula S. Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty. Cancer Treat Rev 2025;136:102944. [Crossref] [PubMed]
11. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy. Lancet 2025;406:603-14.
12. Patel MS. Strategies for the Optimal Management of Dyspnea in Cancer Patients With Advanced Illness. Oncology (Williston Park) 2018;32:583-90.